Supplements

Stapokibart improves sleep domain scores in patients with chronic rhinosinusitis with nasal polyps

In a post-hoc analysis of the phase 3 CROWNS-2 study, stapokibart significantly improved SNOT-22 Sleep domain scores compared to placebo during the 24-week double-blind period. These improvements were maintained or further improved during the 28-week open-label extension and 8-week safety follow-up.

Last updated: Jul 7, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score44/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. [Quality of life improvement with stapokibart in chronic rhinosinusitis with nasal polyps: a post hoc analysis of phase 3 CROWNS-2 study].

observational

Yan B, Jin Z, Zhang L, Wang C · Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery (2026)

Participants: N/A
Duration: 24 weeks double-blind, plus 28 weeks open-label, plus 8-week follow-up
Intervention: Stapokibart (anti-IL-4Rα monoclonal antibody) 300 mg every 2 weeks for 24 weeks, followed by open-label extension for 28 weeks
Outcome: 22-item sinonasal outcome test (SNOT-22) domain scores: Nasal, Ear/facial, Sleep, and Emotion
Effect Size: N/A (specific effect sizes not reported in abstract)
Population: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the phase 3 CROWNS-2 study

Result:

PubMed: 42402685DOI: 10.13201/j.issn.2096-7993.2026.07.010

Mechanism Graph

Stapokibart binds to IL-4 receptor α subunit
↓
Blocks IL-4 and IL-13 signaling pathways
↓
Reduces type 2 inflammation in nasal and sinus mucosa
↓
Improves sinonasal symptoms including sleep disturbance

Limitations

  • ⚠Post-hoc analysis, not pre-specified primary endpoint
  • ⚠Specific effect sizes and p-values for sleep domain not reported in abstract

Frequently Asked Questions

What is stapokibart?▼

Stapokibart is an anti-interleukin-4 receptor α (IL-4Rα) monoclonal antibody that blocks IL-4 and IL-13 signaling pathways.

How was sleep measured in this study?▼

Sleep was assessed using the Sleep domain of the 22-item sinonasal outcome test (SNOT-22), a validated patient-reported outcome measure.

How long did the sleep improvements last?▼

Improvements in sleep domain scores were maintained during the 28-week open-label extension and 8-week safety follow-up period.

What other quality of life domains improved?▼

Stapokibart also significantly improved Nasal, Ear/facial, and Emotion domain scores of the SNOT-22.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Yan B, Jin Z, Zhang L, Wang C. "[Quality of life improvement with stapokibart in chronic rhinosinusitis with nasal polyps: a post hoc analysis of phase 3 CROWNS-2 study].." Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery, 2026. PMID: 42402685 DOI: 10.13201/j.issn.2096-7993.2026.07.010
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.